Livanova plc of London has concluded the PRELUDE study, a 20-patient feasibility study of the Caisson transcatheter mitral valve replacement (TMVR) device the company acquired in 2017. The company said pivotal studies for both the EU and the U.S. markets are either enrolling or will soon will be, but other companies are already into pivotal trials for their TMVR devices. Nonetheless, Paul Buckman, Livanova's general manager for mitral valve devices, said the company expects to compete successfully by presenting clinicians with a best-in-class device because ultimately, "the best technology wins."